Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Symphogen, a developer of recombinant polyclonal antibodies, has acquired the technology and programs of Receptor BioLogix, a developer of developing pan-HER ligand traps to treat cancer and other diseases. Both companies are privately owned. Financial details of the transaction were not disclosed.
Subscribe to our email newsletter
The complex human EGF receptor (HER) family of receptors and growth factor ligands is dysregulated in about half of all solid cancers. Receptor BioLogix’s pan-HER ligand traps are engineered proteins combining an antibody-like element along with multiple HER receptors. They are designed to block the diverse ligands that stimulate tumor growth. Receptor BioLogix’s pan-HER ligand traps are in preclinical development.
Kirsten Drejer, CEO of Symphogen, said: “Receptor BioLogix’s innovative pan-HER ligand trap technology is an excellent fit with our scientific and strategic focus. We are developing novel biologics explicitly designed to address disease complexity, with the goal of achieving better efficacy than single-targeted drugs that fail to account for the complex nature of many diseases.
“We expect our established infrastructure and highly relevant expertise in developing complex biologics will facilitate the rapid progress of the pan-HER cancer program, which we believe has breakthrough potential.”